These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 15052970

  • 1. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer].
    Załeska M.
    Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970
    [No Abstract] [Full Text] [Related]

  • 2. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B, Huang AM, Zhong RB, Han BH.
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
    De Angelis G, De Marinis F, Bigioni D, Migliorino MR, Alma MG, Pigorini F.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A, Soresi E, Boffi R, Nonis A, Noseda A, Cobelli S, Scanni A.
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C, Andratschke N, Jeremic B, Molls M.
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
    Załeska M, Szturmowicz M, Zych J, Roszkowska-Sliz B, Demkow U, Langfort R, Roszkowski-Sliz K.
    Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
    [Abstract] [Full Text] [Related]

  • 11. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM, Massard Zh, Reshetov AV, Nikolaev GV, Volgin GN, Osipov EV, Lomteva EIu, Nokhrin AV, Kakysheva OE.
    Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
    Kakari S, Stringou E, Toumbis M, Ferderigos AS, Poulaki E, Chondros K, Dema A, Kotsovoulou V, Pavlidis N.
    Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.